Cargando…

Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma

BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakai, Masato, Morikawa, Kenichi, Hosoda, Shunichi, Yoshida, Sonoe, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Ohara, Masatsugu, Sho, Takuya, Suda, Goki, Ogawa, Koji, Sakamoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376769/ https://www.ncbi.nlm.nih.gov/pubmed/36158914 http://dx.doi.org/10.4254/wjh.v14.i7.1480

Ejemplares similares

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia
por: Yoshida, Sonoe, et al.
Publicado: (2021)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Tokuchi, Yoshimasa, et al.
Publicado: (2021)

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2022)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2023)

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma
por: Ohara, Masatsugu, et al.
Publicado: (2023)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
por: Kubo, Akinori, et al.
Publicado: (2021)

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma
por: Kohya, Risako, et al.
Publicado: (2023)

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2021)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication
por: Nakai, Masato, et al.
Publicado: (2022)

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
por: Kawagishi, Naoki, et al.
Publicado: (2022)

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
por: Sho, Takuya, et al.
Publicado: (2022)

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2020)

The Serum Mac-2-binding Protein Glycosylation Isomer Dynamics in Acute Liver Injury
por: Seike, Takuya, et al.
Publicado: (2020)

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Usefulness of serum Mac-2 binding protein glycosylation isomer in patients undergoing hepatectomy: A case controlled study
por: Hiyoshi, Masahide, et al.
Publicado: (2019)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment
por: Suda, Goki, et al.
Publicado: (2016)

Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis
por: Kiyoaki, Ito, et al.
Publicado: (2022)

Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis
por: Cho, Sun Young, et al.
Publicado: (2018)

Serum Mac-2 Binding Protein Glycosylation Isomer Concentrations Are Associated With Incidence of Type 2 Diabetes
por: Higashioka, Mayu, et al.
Publicado: (2023)

Application of Mac-2 binding protein glycosylation isomer as a non-invasive biomarker for probing liver disease
por: Tangvoraphonkchai, Kawin, et al.
Publicado: (2022)

Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease
por: Miwa, Takao, et al.
Publicado: (2022)

Biological variation and reference change values of serum Mac‐2–binding protein glycosylation isomer (M2BPGi)
por: Choi, Rihwa, et al.
Publicado: (2022)

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
por: Ohara, Masatsugu, et al.
Publicado: (2018)

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
por: Suda, Goki, et al.
Publicado: (2018)

Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis
por: Migita, Kiyoshi, et al.
Publicado: (2018)

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection
por: Jun, Tomi, et al.
Publicado: (2019)

Diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis
por: Nishikawa, Hiroki, et al.
Publicado: (2019)

Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients
por: Wu, Pei-Shan, et al.
Publicado: (2021)

Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Treatment of hepatitis C in special populations
por: Suda, Goki, et al.
Publicado: (2018)

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
por: Sho, Takuya, et al.
Publicado: (2017)

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases
por: Sho, Takuya, et al.
Publicado: (2018)

Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0otr0igs63ofs5rv4iiug51sf3